Journal of Antimicrobial Chemotherapy (2002) 50, 119-123
© 2002 The British Society for Antimicrobial Chemotherapy
In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients
1 Department of Microbiology–Infectious Diseases, Hôpital Maisonneuve-Rosemont, 5415 Boulevard l’Assomption, Montréal, Québec H1T 2M4; 2 Department of Microbiology, Health Sciences Center, Winnipeg, Manitoba, Canada
Received 13 July 2001; returned 28 December 2001; revised 21 January 2002; accepted 27 March 2002
The in vitro activities of voriconazole, posaconazole, ravuconazole and micafungin were compared with those of fluconazole, itraconazole, ketoconazole, flucytosine and amphotericin B against 164 candidaemia isolates recovered from cancer patients in two Canadian centres. The MIC50 results for ravuconazole, voriconazole, posaconazole and micafungin were 0.01, 0.03, 0.12 and 0.25 mg/L, respectively. The new antifungal agents showed substantial activity against isolates demonstrating in vitro resistance to fluconazole and itraconazole. These results suggest that the newer antifungal agents possess promising activity against invasive Candida isolates, particularly against those with reduced susceptibility to fluconazole and itraconazole.
* Corresponding author. Tel: +1-514-252-3817; Fax: +1-514-252-3898; E-mail: laverdim{at}courrier.umontreal.ca
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. C. Arendrup, G. Garcia-Effron, W. Buzina, K. L. Mortensen, N. Reiter, C. Lundin, H. E. Jensen, C. Lass-Florl, D. S. Perlin, and B. Bruun Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1185 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Trofa, A. Gacser, and J. D. Nosanchuk Candida parapsilosis, an Emerging Fungal Pathogen Clin. Microbiol. Rev., October 1, 2008; 21(4): 606 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chowdhry and W. L. Marshall Analytical Reviews: Antifungal Therapies in the Intensive Care Unit J Intensive Care Med, May 1, 2008; 23(3): 151 - 158. [Abstract] [PDF]
|
|
|
|
|
|
C. Serena, M. Marine, G. Quindos, A. J. Carrillo, J. F. Cano, F. J. Pastor, and J. Guarro In Vitro Interactions of Micafungin with Amphotericin B against Clinical Isolates of Candida spp. Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1529 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dannaoui, O. Lortholary, D. Raoux, M. E. Bougnoux, G. Galeazzi, C. Lawrence, D. Moissenet, I. Poilane, D. Hoinard, F. Dromer, et al. Comparative In Vitro Activities of Caspofungin and Micafungin, Determined Using the Method of the European Committee on Antimicrobial Susceptibility Testing, against Yeast Isolates Obtained in France in 2005-2006 Antimicrob. Agents Chemother., February 1, 2008; 52(2): 778 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Rodriguez, M. Ruiz, F. J. Pastor, G. Quindos, A. Carrillo, and J. Guarro In vitro interaction of micafungin and fluconazole against Candida J. Antimicrob. Chemother., July 1, 2007; 60(1): 188 - 190. [Full Text] [PDF]
|
|
|
|
|
|
H. Seifert, U. Aurbach, D. Stefanik, and O. Cornely In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1818 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Enoch, H. A. Ludlam, and N. M. Brown Invasive fungal infections: a review of epidemiology and management options. J. Med. Microbiol., July 1, 2006; 55(Pt 7): 809 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laverdiere, R. G. Lalonde, J.-G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis J. Antimicrob. Chemother., April 1, 2006; 57(4): 705 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzon, and J. L. Rodriguez-Tudela Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi Antimicrob. Agents Chemother., March 1, 2006; 50(3): 917 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Yan, M. R. Marino, R. A. Smith, V. Kanamaluru, E. M. O'Mara, and D. M. Grasela The Effect of Ravuconazole on the Pharmacokinetics of Nelfinavir in Healthy Male Volunteers J. Clin. Pharmacol., February 1, 2006; 46(2): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Heyn, A. Tredup, S. Salvenmoser, and F.-M. C. Muller Effect of Voriconazole Combined with Micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5157 - 5159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bagg, M P. Sweeney, A. N Davies, M. S Jackson, and S. Brailsford Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer J. Med. Microbiol., October 1, 2005; 54(10): 959 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Golan Overview of transplant mycology Am. J. Health Syst. Pharm., April 15, 2005; 62(suppl_1): S17 - S21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L Carver Micafungin Ann. Pharmacother., October 1, 2004; 38(10): 1707 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, G. Garcia-Effron, and J. L. Rodriguez-Tudela In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates Antimicrob. Agents Chemother., August 1, 2004; 48(8): 3107 - 3111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takakura, N. Fujihara, T. Saito, T. Kudo, Y. Iinuma, S. Ichiyama, and the Japan Invasive Mycosis Surveillance Study Grou National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin J. Antimicrob. Chemother., February 1, 2004; 53(2): 283 - 289. [Abstract] [Full Text] [PDF]
|
|